China Resources Double-Crane Pharmaceutical (600062.SH): Dexmethylphenidate Hydrochloride Extended-Release Capsules Included in National Reimbursement Drug List

Stock News12-08

China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary Henan Zhongshuai Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of Henan Zhongshuai Medicine Technology Co., Ltd.) has successfully included its product, Dexmethylphenidate Hydrochloride Extended-Release Capsules, in the National Reimbursement Drug List (2025) through medical insurance negotiations. The drug will be classified under Category B for reimbursement during the agreement period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153124720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 17:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153124720","market":"fut","top_or_hot":-1,"title":"China Resources Double-Crane Pharmaceutical (600062.SH): Dexmethylphenidate Hydrochloride Extended-Release Capsules Included in National Reimbursement Drug List","media":"Stock News","content":"<p>China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary Henan Zhongshuai Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of Henan Zhongshuai Medicine Technology Co., Ltd.) has successfully included its product, Dexmethylphenidate Hydrochloride Extended-Release Capsules, in the National Reimbursement Drug List (2025) through medical insurance negotiations. The drug will be classified under Category B for reimbursement during the agreement period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Double-Crane Pharmaceutical (600062.SH): Dexmethylphenidate Hydrochloride Extended-Release Capsules Included in National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Double-Crane Pharmaceutical (600062.SH): Dexmethylphenidate Hydrochloride Extended-Release Capsules Included in National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 17:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary Henan Zhongshuai Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of Henan Zhongshuai Medicine Technology Co., Ltd.) has successfully included its product, Dexmethylphenidate Hydrochloride Extended-Release Capsules, in the National Reimbursement Drug List (2025) through medical insurance negotiations. The drug will be classified under Category B for reimbursement during the agreement period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1153124720","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153124720","pubTimestamp":1765186573,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary Henan Zhongshuai Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of Henan Zhongshuai Medicine...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600062":"华润双鹤","BK0188":"融资融券","BK0175":"白马股","BK0010":"央企","BK0239":"医药制造","BK0028":"国家队","BK0185":"二线龙头"},"translate_title":"华润双鹤药业（600062.SH）：盐酸右哌甲酯缓释胶囊纳入国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":1},"content_text":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary Henan Zhongshuai Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of Henan Zhongshuai Medicine Technology Co., Ltd.) has successfully included its product, Dexmethylphenidate Hydrochloride Extended-Release Capsules, in the National Reimbursement Drug List (2025) through medical insurance negotiations. The drug will be classified under Category B for reimbursement during the agreement period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153124720","isCrawlerRequest":true}